Chih-Chiang Hung
Overview
Explore the profile of Chih-Chiang Hung including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
54
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lin Y, Lin C, Man K, Hung C, Hsu H, Chen Y, et al.
Lab Chip
. 2025 Feb;
PMID: 40008895
Preclinical evaluation of anticancer drug efficacy utilizes 2D cell culture systems, tumoroids or experimental animal models, but it suffers from limitations such as inaccurate simulation of tumor microenvironments in living...
2.
Hung C, Wang Y, Shih H, Liu C, He J, Chen J, et al.
Cancer Genomics Proteomics
. 2025 Feb;
22(2):258-270.
PMID: 39993804
Background/aim: Matrix metalloproteinase-9 (MMP-9) has been associated with the development and progression of breast cancer (BCa). However, the relationship between MMP-9 genetic variants and BCa susceptibility remains contentious and inconclusive....
3.
Lin Y, Hung C, Lin G, Tsai I, Lum C, Hsiao T
Cancer Epidemiol
. 2024 Dec;
94():102701.
PMID: 39705763
Background: Breast cancer has been the most frequently diagnosed cancer among women in Taiwan since 2003. While genetic variants play a significant role in the elevated risk of breast cancer,...
4.
Jhaveri K, Neven P, Casalnuovo M, Kim S, Tokunaga E, Aftimos P, et al.
N Engl J Med
. 2024 Dec;
PMID: 39660834
Background: Imlunestrant is a next-generation, brain-penetrant, oral selective estrogen-receptor (ER) degrader that delivers continuous ER inhibition, even in cancers with mutations in the gene encoding ERα (). Methods: In a...
5.
Hung C, Tsai C, Chin Y, Wang Y, Liu C, Lin M, et al.
Cancer Genomics Proteomics
. 2024 Aug;
21(5):502-510.
PMID: 39191502
Background/aim: Matrix metalloproteinase-2 (MMP-2) has been implicated in the pathogenesis of breast cancer (BC). However, there is limited research on the role of MMP-2 genotypes in BC risk. This study...
6.
Chen C, Yi Y, Guu H, Chen Y, Kung H, Chang J, et al.
J Formos Med Assoc
. 2024 Aug;
124(2):112-117.
PMID: 39138104
Background: Breast cancer treatments often have negative effects on fertility, which pose challenges among patients who want to be parents in the future. This study aimed to examine the efficacy...
7.
Hung C, Moi S, Huang H, Hsiao T, Huang C
Sci Rep
. 2024 Mar;
14(1):6324.
PMID: 38491043
Mammographic screening has contributed to a significant reduction in breast cancer mortality. Several studies have highlighted the correlation between breast density, as detected through mammography, and a higher likelihood of...
8.
Wang Y, He J, Tsai C, Tzeng H, Chang W, Pan S, et al.
Life (Basel)
. 2024 Jan;
14(1).
PMID: 38276258
Tissue inhibitor of metalloproteinase-2 (TIMP-2) is an endogenous inhibitor of matrix metalloproteinase-2 and is highly expressed in breast cancer (BC) cases at diagnosis. However, the genetic investigations for the association...
9.
Wu H, Lin C, Tzeng Y, Hung C, Liu S, Yin C, et al.
J Chin Med Assoc
. 2023 Dec;
87(2):226-235.
PMID: 38095571
Background: Multiple pretreatment systemic inflammatory markers (SIMs) have been reported as predictors of pathological complete response (pCR) after neoadjuvant systemic therapy (NST) in patients with breast cancer (BC). However, the...
10.
Wang T, Chang P, Chen W, Hung C, Chen J, Lin Y, et al.
Semin Oncol Nurs
. 2023 Oct;
39(6):151512.
PMID: 37827902
Objective: This study aims to investigate the effectiveness of an upper limb rehabilitation program on the quality of life in patients who had been first diagnosed breast cancer and subsequently...